JP2022546402A - ウイルス感染症を処置するための組成物及び方法 - Google Patents

ウイルス感染症を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2022546402A
JP2022546402A JP2022513124A JP2022513124A JP2022546402A JP 2022546402 A JP2022546402 A JP 2022546402A JP 2022513124 A JP2022513124 A JP 2022513124A JP 2022513124 A JP2022513124 A JP 2022513124A JP 2022546402 A JP2022546402 A JP 2022546402A
Authority
JP
Japan
Prior art keywords
virus
nucleic acid
acid molecule
viral
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513124A
Other languages
English (en)
Japanese (ja)
Inventor
セルハト・グムルーク
Original Assignee
ジー・テック・バイオ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー・テック・バイオ・エルエルシー filed Critical ジー・テック・バイオ・エルエルシー
Publication of JP2022546402A publication Critical patent/JP2022546402A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/02Pentosyltransferases (2.4.2)
    • C12Y204/02036NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22062Caspase-9 (3.4.22.62)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022513124A 2019-08-29 2020-08-28 ウイルス感染症を処置するための組成物及び方法 Pending JP2022546402A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962893460P 2019-08-29 2019-08-29
US62/893,460 2019-08-29
US202062968387P 2020-01-31 2020-01-31
US62/968,387 2020-01-31
US202062976491P 2020-02-14 2020-02-14
US62/976,491 2020-02-14
US202062985597P 2020-03-05 2020-03-05
US62/985,597 2020-03-05
PCT/US2020/048370 WO2021041787A1 (fr) 2019-08-29 2020-08-28 Compositions et méthodes pour le traitement d'infections virales

Publications (1)

Publication Number Publication Date
JP2022546402A true JP2022546402A (ja) 2022-11-04

Family

ID=74686046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513124A Pending JP2022546402A (ja) 2019-08-29 2020-08-28 ウイルス感染症を処置するための組成物及び方法

Country Status (11)

Country Link
EP (1) EP4022072A4 (fr)
JP (1) JP2022546402A (fr)
KR (1) KR20220095183A (fr)
CN (1) CN114761566A (fr)
AU (1) AU2020335886A1 (fr)
BR (1) BR112022003814A2 (fr)
CA (1) CA3149041A1 (fr)
IL (1) IL290826A (fr)
MX (1) MX2022002211A (fr)
WO (1) WO2021041787A1 (fr)
ZA (1) ZA202202370B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220282279A1 (en) * 2021-03-06 2022-09-08 Serhat Gumrukcu Compositions and methods for treating and preventing coronavirus infections
WO2023220086A1 (fr) * 2022-05-13 2023-11-16 Suntec Medical, Inc. Méthode de traitement d'une maladie infectieuse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
WO2012170431A2 (fr) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Systèmes perfectionnés de commutation génique
CA2943047C (fr) * 2014-06-20 2023-03-14 F. Hoffmann-La Roche Ag Antigene e de virus adn de l'hepatite marque et son utilisation lors d'un criblage de substances antivirales

Also Published As

Publication number Publication date
KR20220095183A (ko) 2022-07-06
CA3149041A1 (fr) 2021-03-04
WO2021041787A1 (fr) 2021-03-04
IL290826A (en) 2022-04-01
EP4022072A4 (fr) 2023-09-06
CN114761566A (zh) 2022-07-15
AU2020335886A1 (en) 2022-03-17
EP4022072A1 (fr) 2022-07-06
BR112022003814A2 (pt) 2022-05-24
MX2022002211A (es) 2022-05-24
ZA202202370B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
EP4037708B1 (fr) Vaccins contre le virus de l'hépatite b et méthodes de traitement du vhb
KR20190135000A (ko) Aav 벡터를 기반으로 하는 인플루엔자 백신
CN111818942A (zh) 非病毒dna载体以及其用于产生抗体和融合蛋白的用途
JP2019509029A (ja) Hivワクチン接種および免疫療法
Scher et al. Rhabdoviruses as vectors for vaccines and therapeutics
JP2022546402A (ja) ウイルス感染症を処置するための組成物及び方法
US20230190917A1 (en) Viral vaccine vector for immunization against a betacoronavirus
CA3166132A1 (fr) Procedes de prevention ou de traitement d'une lesion ou d'une defaillance d'organe induite par un virus au moyen d'un dimere d'il-22
US20150337015A1 (en) Antiviral rift valley fever virus peptides and methods of use
EP3624825A1 (fr) Virus oncolytique recombinant
US20210238232A1 (en) Compositions and methods for treating viral infections
KR20010033062A (ko) 렌티바이러스성 벡터의 치료학적 용도
US20220282279A1 (en) Compositions and methods for treating and preventing coronavirus infections
US20160030518A1 (en) Compositions and methods for inhibiting viral activity
KR20240005903A (ko) 백신 전달을 위한 비바이러스성 dna 벡터
CN113975299B (zh) 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用
JP2011506606A (ja) フィロウイルスまたはアレナウイルス感染の暴露前または暴露後の治療法
JP4806187B2 (ja) B型肝炎ウイルスの治療のためのl−fmauとの併用療法
JP2023551821A (ja) ウイルス感染を治療するための方法及び組成物
KR20240011714A (ko) 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
CA3218126A1 (fr) Compositions de vecteurs d'adn non viraux lyophilisees et leurs utilisations
WO2024015803A2 (fr) Arn crypté et ses procédés d'utilisation
WO2020210003A9 (fr) Particules de type virus et leurs utilisations
Croyle et al. 892. Purification of Recombinant Lentiviral V 892. Purification of Recombinant Lentiviral Vector by Anion Exchange Chromatography

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924